<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04519762</url>
  </required_header>
  <id_info>
    <org_study_id>R38/2020</org_study_id>
    <nct_id>NCT04519762</nct_id>
  </id_info>
  <brief_title>Levels of 'Hypophosphatemia Affect Outcome of Septic Patients in ICU</brief_title>
  <official_title>Hupophosphatemia Levels Deleteriously Affect Outcome of Patients With Severe Sepsis/Septic Shock Admitted to ICU</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ain Shams University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ain Shams University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The current study aimed to determine the incidence of hypophosphatemia (HP) among severe&#xD;
      sepsis/septic shock patients admitted to ICU and its impact on morbidity and mortality rates&#xD;
      of these patients, and to evaluate the impact of phosphorous supplemental therapy (PST) on&#xD;
      such outcomes.Thus, this study will hypothesize that diagnosis and management of HP may be&#xD;
      advantageous for reduction of morbidity and mortality rates of septic patients admitted to&#xD;
      ICU.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will include all patients admitted to ICU with or developing severe sepsis or&#xD;
      septic shock within 24-hr after admission to ICU. Patients will be categorized according to&#xD;
      at-admission inorganic phosphate (Pi) level into normophosphatemia group and hypophosphatemia&#xD;
      group (HP) (mild, moderate and severe HP). All patients will be evaluated using Sequential&#xD;
      Organ Failure Assessment (SOFA) and Acute Physiology and Chronic Health Evaluation II score&#xD;
      (APACHE II) and blood samples will be collected for ELISA estimation of serum Pi, human&#xD;
      C-reactive protein (CRP), L-lactate, CBC picture , serum electrolytes and kidney and liver&#xD;
      function tests. Serum Pi level will be re-estimated immediately and 24-hr after full dose&#xD;
      administration. Outcomes will include the 28-day ICU morbidity and mortality rates and their&#xD;
      relation to HP severity and PST administration.&#xD;
&#xD;
      Patients who will fulfill the inclusion criteria will be selectively divided into two groups&#xD;
      according to estimated level of serum Pi: Control group will include patients with serum Pi&#xD;
      &gt;2.5 mg/dl and Study group will include patients having serum Pi&lt;2.5 mg/dl and will be&#xD;
      further sub-grouped according to severity of HP into mild HP (2-2.5 mg/dl), moderate (1-1.9&#xD;
      mg/dl) or severe (&lt;1 mg/dl).&#xD;
&#xD;
      Central venous catheter will be inserted for all patients enrolled in the study via the&#xD;
      jugular or subclavian vein. Then, baseline hemodynamic parameters and central venous pressure&#xD;
      (CVP) will be estimated and will be continuously monitored. Arterial blood samples will be&#xD;
      obtained anaerobically and collected in heparinized tubes for estimation of arterial blood&#xD;
      gas and pH.&#xD;
&#xD;
      Sepsis management: Patients were managed according to guidelines of Surviving&#xD;
&#xD;
      Sepsis Campaign; briefly:&#xD;
&#xD;
        1. Fluid therapy&#xD;
&#xD;
        2. Vasoactive drug therapy&#xD;
&#xD;
        3. Intropics&#xD;
&#xD;
        4. Antibiotic therapy&#xD;
&#xD;
      HP management regimen follows:&#xD;
&#xD;
        1. Calculation of supplementation dose according to the equation: phosphate dose (in mmol)&#xD;
           = 0.5 x body weight x (1.25 - [serum Pi]).&#xD;
&#xD;
        2. Preparation that will be used: GlycophosÂ®, Fresenius Kabi Egypt (organic phosphate&#xD;
           solution 1mmol/ml). Vial 20 ml (1ml contains 1mmol of phosphate and 2mmol of sodium).&#xD;
&#xD;
        3. Dilution: will be diluted prior to parenteral administration. 20 ml of&#xD;
           sodium-glycerophosphate diluted in 30 cc of dextrose 5% administered by syringe pump (50&#xD;
           mL).&#xD;
&#xD;
        4. The total calculated dose will be divided into three doses every 8 hours.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 15, 2020</start_date>
  <completion_date type="Anticipated">December 15, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 15, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mortality (No.)</measure>
    <time_frame>15 September 2020 - 15 December 2020 (3 months)</time_frame>
    <description>Assessment of mortality Assessment of mortality</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mortality (%)</measure>
    <time_frame>15 September 2020 - 15 December 2020 (3 months)</time_frame>
    <description>Assessment of mortality</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Hypophosphatemia</condition>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Management of sepsis/ septic shock via fluids, antibiotics, vasopressors and inotropes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Study group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Management of sepsis/ septic shock in addition to management of hypophosphatemia.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glycophos (Sodium Glycerophosphate)</intervention_name>
    <description>Management of hypophosphatemia via Glycophos Management of severe sepsis/septic shock via fluid therapy, antibiotics, vasopressors and inotropics.</description>
    <arm_group_label>Study group</arm_group_label>
    <other_name>Saline</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Antibiotics</intervention_name>
    <description>Management of severe sepsis/septic shock via fluid therapy, antibiotics, vasopressors and inotropics.</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>Study group</arm_group_label>
    <other_name>saline</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Inotropes</intervention_name>
    <description>Management of severe sepsis/septic shock via fluid therapy, antibiotics, vasopressors and inotropics.</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>Study group</arm_group_label>
    <other_name>saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patients with severe sepsis and/or septic shock within 24 hours of admission to ICU&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  children and adulthoods younger than 18 years&#xD;
&#xD;
          -  pregnancy&#xD;
&#xD;
          -  severe hemorrhagic shock&#xD;
&#xD;
          -  maintenance on immunosuppressant therapy for any indication&#xD;
&#xD;
          -  patients who are expected to die within the first 24 hours after admission&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ahmed Kamal, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ain Shams University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Noha Hussien, Dr.</last_name>
    <phone>+201222830981</phone>
    <email>nohasayedhussien@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sherif Anis, Dr.</last_name>
    <phone>+2001222421674</phone>
    <email>sherifganis@hotmail.com</email>
  </overall_contact_backup>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 12, 2020</study_first_submitted>
  <study_first_submitted_qc>August 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 20, 2020</study_first_posted>
  <last_update_submitted>August 17, 2020</last_update_submitted>
  <last_update_submitted_qc>August 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ain Shams University</investigator_affiliation>
    <investigator_full_name>Noha Sayed Hussien</investigator_full_name>
    <investigator_title>Clinical Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypophosphatemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

